NMD4C and MDC Announce Plans for Neuromuscular Community of Practice
Together with Muscular Dystrophy Canada we are thrilled to announce a new community of practice (COP) initiative for healthcare professionals (HCP) who care for patients with neuromuscular disease.
In response to the dynamic and rapidly advancing landscape of therapies for neuromuscular disorders (NMDs), this CoP will address the need for a centralized hub for neuromuscular HCPs, fostering collaboration, knowledge exchange, and skill enhancement to elevate NMD research and care across Canada.
Providing Support Where It’s Needed
The CoP will offer opportunities for knowledge exchange and joint upskilling for neuromuscular HCPs nationwide. Many Canadian HCPs encounter limitations in exchanging ideas and accessing tailored neuromuscular training from outside of their individual healthcare centers. The CoP will bridge these gaps to provide specific training opportunities to collectively strengthen and unite neuromuscular HCPs across Canada.
Focused Areas of Impact
We will focus initially on key areas where specific training and collaboration will provide the most benefit, including training for conducting clinical trials in Canada, advancing physical medicine and rehabilitation, and conducting outcome measures for NMD therapies, which are crucial for supporting therapy reimbursement in Canada.
Who Is This CoP For?
The CoP will facilitate connections primarily among rehabilitation specialists, physiatrists, and clinical trial coordinators. We aim to create an inclusive environment where expertise from a variety of roles is welcomed, and we invite neuromuscular stakeholders from beyond these roles to join us.
How to Get Involved
Individuals who are interested in participating in the CoP can express their interest by joining the NMD4C. If you are already a member of the network, we will provide updates soon on how you can participate in the CoP! Join the NMD4C to be contacted about the CoP!
For more information, please visit the CoP web page or contact the Community of Practice Manager Dr. Maria Masnata.
Read next...
Zolgensma® Safety Update and CPNG Guidance for Families
The Canadian Pediatric Neuromuscular Group (CPNG) has issued a statement for families regarding recent reports of tumours in children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy for spinal muscular atrophy (SMA). The statement outlines current evidence, considerations for follow-up care, and information for families and healthcare providers.
Could You Be Our Next Awardee? Meet Jules Granet, NMD4C’s 2026 Publication of the Year Awardee
Nominations are open till by 18 January 2027!
In 2026, Jules Granet, a PhD Candidate at McGill University and trainee in Dr. Natasha Chang’s laboratory received an NMD4C Publication of the Year Award for research investigating how muscle stem cell dysfunction contributes to impaired muscle regeneration in Duchenne muscular dystrophy. Nominate yourself or a neuromuscular colleague whose research, clinical care, leadership, advocacy, or community contributions deserve to be recognized.
Early Bird Registration Now Open: 8th Ottawa International Conference On Neuromuscular Disease & Biology
We are happy to announce that early bird registration is now open for the 8th Ottawa International Conference On Neuromuscular Disease & Biology which will be held on October 14-16, 2027 at the Fairmont Château Laurier in Ottawa, Canada. Now under the leadership of NMD4C Investigators; Dr. Mireille Khacho, Dr. Hanns Lochmuller, Dr. Bernard Jasmin, and Dr. Rashmi Kothary.